These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36602752)

  • 1. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions.
    Gupta K; Hirsch JR; Kalsi J; Patel V; Gad MM; Virani SS
    Curr Atheroscler Rep; 2023 Jan; 25(1):31-41. PubMed ID: 36602752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference.
    Gupta K; Balachandran I; Foy J; Hermel M; Latif A; Krittanawong C; Slipczuk L; Baloch F; Samad Z; Virani SS
    Curr Atheroscler Rep; 2023 Jun; 25(6):309-321. PubMed ID: 37086374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.
    Grundy SM; Stone NJ;
    Ann Intern Med; 2019 Jun; 170(11):779-783. PubMed ID: 31132793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference.
    Gupta K; Rawlley B; Meloche C; Minhas AMK; Hermel M; Slipczuk L; Sheikh S; Khoja A; Vaughan EM; Dalakoti M; Virani SS
    Curr Atheroscler Rep; 2024 Aug; 26(8):367-381. PubMed ID: 38829515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid management beyond the guidelines.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):384-389. PubMed ID: 31669499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions.
    Lee MT; George J; Shahab H; Hermel M; Rana JS; Virani SS
    Curr Atheroscler Rep; 2022 Jan; 24(1):61-72. PubMed ID: 35080715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors.
    Shaw PB
    Am J Manag Care; 2021 Mar; 27(4 Suppl):S63-S69. PubMed ID: 33710845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population.
    Iqbal S; Sabbour HM; Siddiqui MS; Tikriti AA; Santos RD; Buckley A
    Clin Ther; 2022 Oct; 44(10):1297-1309. PubMed ID: 36127165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.